Laurus Labs enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,17,790	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
24.5	113	99.5	139	45.7
120	131	130	4.6	11.1
2,397	2,397	2,693	2,507	1,972
1,20,283	—	—	—	—
2,373	2,285	2,594	2,368	1,926
₹2,228.09	—	—	—	—

8,579	7,829	7,296	6,623	6,021
27.9%	30.6%	36.9%	37.9%	32.8%
0.02×	—	—	—	—

15.38×	—	—	—	—
50.52×	—	—	—	—
63.75×	—	—	—	—
217.29×	—	—	—	—
7,823	6,813	5,554	5,041	6,041
2,381	1,778	1,055	778	1,592
1,887	1,298	625	393	1,268
—	1,624	602	666	994
554	554	−39.4	−12.6	3.7
—	511	−95.5	−62.9	−35.8
—	1,070	641	678	990

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LAURUSLABS₹2,181.90

Laurus Labs Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB GLAND MANKIND BIOCON ALKEM LUPIN FORTIS GLENMARKMcap ₹1.18L Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,17,789.9
- Cash, Equiv & ST Investments	45.7	138.9	99.5	112.7	24.5
+ Minority Interest	11.1	4.6	130.0	131.3	120.5
+ Total Debt	1,972.0	2,507.1	2,693.1	2,397.5	2,397.5
Enterprise Value	—	—	—	—	1,20,283.4
Net Debt (memo)	1,926.3	2,368.1	2,593.5	2,284.8	2,373.0
EV per Share	—	—	—	—	2,228.09

Total Capital	6,020.6	6,622.6	7,295.6	7,828.9	8,578.5
Total Debt/Total Capital	32.75	37.86	36.91	30.62	27.95
Total Debt/EV	—	—	—	—	0.02

EV/Sales	—	—	—	—	15.38
EV/EBITDA	—	—	—	—	50.52
EV/EBIT	—	—	—	—	63.75
EV/Free Cash Flow	—	—	—	—	217.29
Reference Items — Trailing FY Values
Sales	6,040.6	5,040.8	5,554.0	6,812.9	7,822.5
EBITDA	1,592.2	777.5	1,055.3	1,777.7	2,380.9
EBIT	1,268.1	392.9	625.2	1,297.7	1,886.9
Operating Cash Flow	993.9	665.7	601.7	1,623.5	—
Free Cash Flow	3.7	-12.6	-39.4	553.6	553.6
FCFF (free cash flow to the firm)	-35.8	-62.9	-95.5	511.4	—
Capital Expenditure	990.2	678.3	641.0	1,070.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.